The approval of antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)/PD-L1 has significantly transformed the cancer treatment landscape, leading to a number of clinical trials assessing ICI efficacy.4 This evidence concerns the gene PDCD1 and cancer.